Table 1.
Characteristics | Era 1 150 patients AS | Era 2 117 patients MS | P |
Gender | |||
Male | 82 (54.7) | 63 (52.5) | 0.89 |
Age, median ± SD | 33.4 ± 15.1 | 34.1 ± 16.1 | 0.25 |
Pathological subtype | |||
Nodular sclerosis | 88 (58.7) | 71 (59.2) | |
Non classified | 17 (11.3) | 22 (18.3) | |
Mixed cellularity | 31 (20.7) | 12 (10.0) | 0.53 |
Lymphocyte predominance | 12 (8.0) | 9 (7.5) | |
Lymphocyte depleted | 2 (1.3) | 6 (5.0) | |
B symptoms | 99 (66.0) | 76 (65.0) | 0.85 |
Bulky disease (> 7 cm) | 91 (60.3) | 67 (57.3) | 0.74 |
Clinical stage | 0.12 | ||
I | 12 (8.0) | 9 (7.7) | |
II | 61 (40.7) | 45 (38.5) | |
III | 35 (23.3) | 27 (23.1) | |
IV | 42 (28.0) | 36 (30.8) | |
Treatment failure | 43 (28.7) | 36 (30.8) | 0.70 |
Death | 20 (13.3) | 14 (12.0) | 0.73 |
AS: Anatomical staging; MS: Metabolic staging.